Hepatitis C Screening
National Clinical Guideline No. 15

NPSO Conference October 2017

Dr Lelia Thornton
Health Protection Surveillance Centre
National Hepatitis C Strategy 2011-2014

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>23a</td>
<td>Access to diagnostic facilities</td>
</tr>
<tr>
<td>24b</td>
<td>Screening of prisoners</td>
</tr>
<tr>
<td>26</td>
<td>Screening of migrants</td>
</tr>
<tr>
<td>27a</td>
<td>Targeted antenatal screening</td>
</tr>
<tr>
<td>27b</td>
<td>Review evidence on antenatal screening</td>
</tr>
<tr>
<td>28</td>
<td>Screening at harm reduction</td>
</tr>
<tr>
<td>29b</td>
<td>Standard protocols for testing and diagnosis</td>
</tr>
</tbody>
</table>
Rationale for a national guideline

- With the development of new treatments the paradigm has shifted towards elimination
- Ireland has committed to a WHO target to eliminate HCV by 2030
- Aim to offer treatment to all
- However, up to 60% of those with HCV infection in Ireland are undiagnosed
- Cases may go undetected for decades, with significant future healthcare costs and risk of ongoing transmission
- Screening already in many settings but no comprehensive national guidance
- WHO*: “....national testing policies are needed, as are increased investments in HCV screening services in order to reach the goal of elimination”

*WHO Global Health Sector Strategy on Viral hepatitis 2016-2021
Summary of key questions

• Who should be offered screening for hepatitis C?
  • Specific population groups or risk factors

• Is there a role for birth cohort screening?

• How should screening be performed?
  • Test, specimen, frequency?

• Interventions to increase uptake and linkage to care
Who should be offered HCV screening?

Strong recommendations

✓ Those who have ever **injected drugs**
✓ **Non-injecting** drug users
✓ **Prisoners** or former prisoners
✓ **Homeless** people with risk behaviours
✓ **Migrants** intermediate/ high prevalence of HCV
✓ **Infants** of HCV-RNA positive women
✓ Men who have sex with men (**MSM**)
✓ People **on renal dialysis** or kidney transplant
✓ Recipients of substances of human origin
  ✓ blood or blood components
  ✓ anti-D immunoglobulin
Who should be offered HCV screening?
Conditional recommendations

- Those with a **tattoo** - decades ago, non-professional settings, prisons, high prevalence countries, poor infection control
- **Household** contacts – certain circumstances
- Recipients of **solid organ transplants**
- Medical or dental **treatment abroad** – high prevalence countries and poor infection control
- **Sexual** partners of known HCV cases:
  - If the case or contact is also HIV positive
  - If the HCV-infected case is an injecting drug user
- Commercial sex workers

Screening should be considered
Birth cohort screening

• Birth cohort screening – requires health technology assessment

Request for HTA submitted to HIQA. Included in prioritisation process – scored highly.
Implementation

• Who will be involved in implementation?
  • A range of services and sectors
    • HSE services, general practice, non-governmental organisations

• Areas of work
  • Education and training
  • Raising awareness
  • Access to testing
    • Existing services
    • Outreach services
    • New settings/new services

  • Linkage to care
  • Integration of services
  • Overcoming language and cultural barriers to testing
  • Monitoring and evaluation
## Implementation plan

<table>
<thead>
<tr>
<th>Barriers to implementation</th>
<th>Facilitators to implementation</th>
<th>Possible actions to facilitate screening</th>
<th>Who will be responsible for implementation</th>
<th>Other stakeholders</th>
<th>Specific action required by GDG</th>
</tr>
</thead>
<tbody>
<tr>
<td>Some may not perceive they are at risk (e.g., those that inject steroids).</td>
<td>Current practice for those attending HIV services, and methadone maintenance, and 24-hour GPs.</td>
<td>Awareness raising amongst public and other HCWs for those not attending addiction services and for those who have used drugs in the past. Outreach testing services; targeted testing outside addiction services e.g., in GP. Education programmes in addiction services.</td>
<td>HSE Social Inclusion Primary Care, Addiction services, HSE, NICE, and those providing outreach community treatment.</td>
<td>Patient groups, NGOs, needle exchange sites, new consultants responsible for vulnerable patients in St. James's Hospital and Mater Hospital, Relevant faculties and societies (CSOP, IDS, ISCM, Public Health, Pathology) Diagnostic laboratories.</td>
<td>Consult with stakeholders and disseminate final recommendations. Awareness raising for public/risk group.</td>
</tr>
<tr>
<td>Lack of awareness amongst HCWs. Fear of testing. Unwillingness to admit behaviour to HCWs. Failure to test in patients who may be at risk.</td>
<td>Current practice in addiction services.</td>
<td>Awareness raising amongst public and other HCWs for those not attending addiction services and for those who have used drugs in the past. Outreach testing services; targeted testing outside addiction services e.g., in GP. Education programmes in addiction services. Referral pathways to care for detected cases. Care co-ordination and support (e.g., HSE and/or peer support) to support retention in care. Community treatment services.</td>
<td>HSE Social Inclusion Primary Care, Addiction services, HSE, NICE, and those providing outreach community treatment.</td>
<td>Patient groups, NGOs, new consultants responsible for vulnerable patients in St. James's Hospital and Mater Hospital, Relevant faculties and societies (CSOP, IDS, ISCM, Public Health, Pathology) Diagnostic laboratories.</td>
<td>Consult with stakeholders and disseminate final recommendations. Awareness raising for public/risk group.</td>
</tr>
</tbody>
</table>

Screening should be offered to all those who have used unprescribed or illicit drugs by a route other than injecting (non-injecting drug use [NIDU]), if there is a probability of transmission of infection by the route of administration. This includes those who currently use intranasal drugs (i.e., sniff, snort), or have done so in the past, or share other equipment or drugs where there is a risk of contamination with the blood of others.
<table>
<thead>
<tr>
<th>Barriers to implementation</th>
<th>Facilitators to implementation</th>
<th>Policy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Recommendation 5 and 6 - People who currently use or have a history of injecting drugs</strong></td>
<td>All those who have ever injected unprescribed or illicit drugs should be offered screening, including performance enhancing drugs like steroids, and novel</td>
<td></td>
</tr>
<tr>
<td>Some may not perceive they are at risk (e.g. those that inject steroids).</td>
<td>Current practice for those attending HSE Addiction Services and methadone level 1 and 2 GPs.</td>
<td></td>
</tr>
<tr>
<td>Poor venous access.</td>
<td>HepCare project.</td>
<td></td>
</tr>
<tr>
<td>Fear of testing of subsequent treatment.</td>
<td>A number of NGOs providing education and peer support.</td>
<td></td>
</tr>
<tr>
<td>Unwillingness to admit behaviour to HCW.</td>
<td>Needle exchange sites could be a setting to encourage testing.</td>
<td></td>
</tr>
<tr>
<td>Access to testing for those not in services.</td>
<td>Safe injecting facilities being developed.</td>
<td></td>
</tr>
<tr>
<td>Payment for testing if not in addiction services or don’t have GMS card.</td>
<td>MedLIS.</td>
<td></td>
</tr>
<tr>
<td>Resources within addiction services.</td>
<td>Lack of computerised system to indicate when last test performed Laboratory resources.</td>
<td></td>
</tr>
<tr>
<td>Lack of computerised system to indicate when last test performed Laboratory resources.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Screening should be offered to all those who have used unprescribed or illicit drugs by the route of administration. This includes those who currently use intravenous drugs. It is important to avoid contamination with the blood of others.

| Some may not perceive they are at risk. |
| Lack of awareness amongst HCWs. |
| Fear of testing. |
| Unwillingness to admit behaviour to HCW. |
| Access to testing for those not in services. |
| Payment for testing. |
| Laboratory resources. | Current practice in addiction services. | |

<p>| | | |
| | | |
| | | |</p>
<table>
<thead>
<tr>
<th>Migrants</th>
</tr>
</thead>
</table>

### Recommendation 10 - Migrants

Migrants from a country with an intermediate to high prevalence of HCV (anti-HCV ≥ 2%) should be offered screening.

<table>
<thead>
<tr>
<th>Barriers to implementation</th>
<th>Facilitators to implementation</th>
<th>Possible actions to facilitate screening</th>
<th>Who will implement</th>
</tr>
</thead>
<tbody>
<tr>
<td>There is no dedicated health service for screening of migrants except for those who are asylum seekers. Many migrants may have poor access to health services due to language, financial, cultural, or legal barriers. Migrants are a diverse group with varying health needs and social circumstances. Different strategies are needed for different groups. There may be a lack of perceived risk. Fear of stigmatising migrants. Access to and payment for testing Laboratory resources.</td>
<td>Asylum seeker and refugee health programme is in place. HSE Social Inclusion/ Primary Care have commissioned SafetyNet to provide outreach services for some newly arrived refugees. This sets a precedent model for outreach services. Migrant screening guidelines are already in place for a range of infectious diseases including HCV (level of 3%). Some GPs are offering services to migrant populations in different languages. New HSE Intercultural Health Strategy is being developed.</td>
<td>Awareness raising amongst public and HCPs. Culturally appropriate information material. Education sessions in community venues frequented by migrants. Outreach testing in community (e.g. religious venues, cultural centres). Establishment by HSE of a testing service or HSE support for outreach testing services by NGOs as for HIV. Translation and interpretation services. Targeted programmes within GP. Inclusion in the new intercultural health strategy</td>
<td>HSE Social Care; GP services, NGOs community care</td>
</tr>
</tbody>
</table>
## Facilitators and barriers/challenges

### Facilitators
- Current practice in many services
- Availability of safe and effective treatments
- Support from key stakeholders
- Initiatives and services such as Community Response, SafetyNet, HepCare Europe, many more – testing, education and peer support
- Rainbow Clinic
- Excellent lab services
- MedLIS
- Many more...

### Barriers/challenges
- Vulnerable and difficult to reach population groups
- Lack of access to screening or treatment services
- Loss to follow-up – mobile pops
- Lack of awareness – public and health professionals
- Language/cultural barriers
- Lab resources – volume
- Limited resources for contact tracing
- Poor/absent IT systems
- Many more.....
Support for implementation

- Launch by Minister Catherine Byrne
- Endorsement by Minister Simon Harris with letters to HSE and key agencies
- HSE 2017 service plan:
  - “Support the development and implementation of relevant national clinical guidelines (…hepatitis C screening…) ensuring that the essential clinical leadership is in place”
  - “…progress the recommendations of the national clinical guidelines on hepatitis C screening (when published) within available funding”
- HSE 2018 service plan?
- Support of Department of Health
HSE National Hepatitis C Treatment Programme

• Very successful to date
• >2,000 patients treated over the past 2 years
• Essential facilitator for implementation of the screening guideline
• Temporary suspension of programme > temporary barrier to communication about screening recommendations
Resources

• Will require some funding for full implementation
• Budget impact analysis: €1.1m annually for 5 years
  – Additional testing, additional services for key risk groups, information and promotion
• Since 2015, €30m annually for HCV drug treatment
• Many of recommendations are budget neutral – guidelines will help to standardise and streamline practice
Elimination of hepatitis C as a public health concern in Ireland

**Recommendation 27**

27.2 A national HCV programme with a mandate spanning the entire HCV continuum of care, including prevention, screening and treatment, should be established.
# Guideline Development Group

Lelia Thornton  
HSE Health Protection Surveillance Centre (Chair)

Colm Bergin  
St James’s Hospital

Margaret Bourke  
HSE Addiction Services, CHO 7

Jeff Connell  
National Virus Reference Laboratory,

Grainne Courtney  
St James’s Hospital

Walter Cullen  
University College Dublin

Orla Cunningham  
Coombe Women & Infants University Hospital

Cillian De Gascun  
National Virus Reference Laboratory

Sinead Donohue  
Department of Public Health, HSE South East

Richard Drew  
Children’s University Hospital, Temple Street and  
The Rotunda Hospital

Orla Ennis  
Department of Public Health, HSE East

Paula Flanagan  
HSE Health Protection Surveillance Centre

John Gallagher  
Occupational Medicine, HSE South

Elizabeth Keane  
Department of Public Health, HSE South

Shay Keating  
National Drug Treatment Centre;

Jack Lambert  
Mater Misericordiae University Hospital

Chantal Migone  
HSE and WHO Geneva

Joanne Moran  
National Virus Reference Laboratory and HSE  
Health Protection Surveillance Centre

Lar Murphy  
Community Response

Frances Nangle  
Irish Prison Service

Connor  
Irish Prison Service

Ursula Norton  
HSE National Office for Social Inclusion

Diane Nurse  
Mountjoy St Medical Practice

Austin O'Carroll  
Irish Blood Transfusion Service and National  
Virus Reference

Niamh O'Flaherty  
Irish Blood Transfusion Service

Joan O'Riordan  
Community Response and the Hepatitis C  
Partnership

Nicola Perry  
HSE Health Protection Surveillance Centre

Eve Robinson  
HSE National Hepatitis C Treatment  
Programme

Michele Tait  
HSE National Hepatitis C Treatment  
Programme
Acknowledgements

NCEC  Kathleen MacLellan, Rosarie Lynch, Sarah Condell
External reviewers  Susan Hahné, Magdalena Rosińska
HPSC  Niamh Murphy, Kirsty MacKenzie, Margaret Mclver, Lucia Mullen, Gerry Reid, Patricia Garvey, Mary O’Riordan
HIQA  Michelle O’Neill, Mairin Ryan
NUIG  Declan Devane, Francesca Wuytack
HSE Health and Wellbeing  Kevin Kelleher, John Cuddihy, Julie Heslin
HSE Librarian  Helen Clark
Individuals who provided expert advice  Suzanne Norris, Jennifer Kieran, Joe Doyle, Lynda Sisson, Joe Barry, Karina Butler, Gerard Sheridan, Niall Mulligan

All those who provided feedback during the consultation process